Category Archives: Immunology

Trinitys New Immunology Research Centre Seeks Funding from SFI – The University Times

Sinad Baker for The University Times

Trinitys newest research centre will find out in early May whether they will receive funding from Science Foundation Ireland (SFI), after a round of interviews and applications that will determine the future of the ambitious immunology institution.

Trinity is currently seeking funding from the Science Foundation Ireland (SFI), to establish the INNATE Inflammation and Immunology Research Centre in the Trinity Biomedical Sciences Institute (TBSI).

In an email to The University Times, Prof Andrew Bowie, the Head of Immunology in Trinity, confirmed that the centre has a final interview on March 1st, and should receive SFIs final decision in early May.

Bowie declined to comment further, due to the sensitive information involved in the application, which is still being considered by SFI.

SFI funding would not only see the creation of the centre but also the refurbishment of a space in TBSI in which it will be housed.

The new centre will follow a similar model to that of other Trinity research institutes, collaborating with industry and integrating researchers from other Irish universities, including University College Dublin (UCD) and Maynooth University. The centre will specialise in research on the immune system and inflammation, a bodily reaction at the centre of many diseases, including arthritis, diabetes, cancer and bowel disease.

One of the key members of the new centre is expert in immunology Prof Luke ONeill. ONeill was recently granted a lab by GlaxoSmithKline (GSK) in Stevenage, England where he will act as Trinity supervisor to two Trinity PhD students, whom GSK will fund to work with their scientists, researching immunology and inflammatory diseases. Elected as a Fellow in 2016 to the prestigious Royal Society, ONeill is one of Trinitys most successful researchers, and has attracted millions in researching funding over the years.

At a meeting of Trinitys Finance Committee in December, the committee noted that the INNATE proposal has the potential to generate a number of financial and strategic benefits for Trinity. The establishment of the centre will also include refurbishment costs for a space in TBSI, with the committee noting that the costs for the space should come from Trinitys funding contribution to the centre. Rental costs for any additional space will be met, however, by INNATE.

The committee also noted that the Faculty of Health Sciences should make a contribution to the refurbishment of the space. If the bid for funding from SFI is successful, the finance committee requested that INNATE would re-engage with the Faculty of Health Science in order to try and secure additional financial support. However if the application is unsuccessful it was was agreed that no refurbishment of TBSI would take place.

SFI currently provides funds for three research centres in Trinity: the Centre for Future Networks and Communications research (CONNECT), the Centre for Advanced Materials and Bio-Engineering Research (AMBER) and ADAPT, which specialises in digital technology. In February, Trinity received 2 million in funding from SFI for the development of the Colleges infrastructure, and numerous principal investigators and Trinity staff rely on funding from the organisation to complete their research. In 2015/16, 46 per cent of total research funding in Trinity came from SFI.

Read this article:
Trinitys New Immunology Research Centre Seeks Funding from SFI - The University Times

‘Bat Pack’ at Duke-NUS allows researchers to study immunology – Duke Chronicle

News By Sarah Haurin | Tuesday, March 14 courtesy of Wikimedia Commons

Researchers atDuke-National University of Singapore Medical School are studying why bats are able to carry diseases.

Bats can carry deadly diseases like Ebola without being infected by them, and scientists want to know how.

A group at the Duke-National University of Singapore Medical School is utilizing a colony of batsnicknamed the "Bat Pack"fortheir immunological research.Led by Linfa Wang, professor and director of the Emerging Infectious Diseases Programme at Duke-NUS, the group conducts research on the evolution and immunology of bats.

"For the past decade or so, bats are increasingly being recognized as one of the most important, if not the most important, natural reservoir hosts for different emerging zoonotic pathogens," research fellow JustinNg said, referring to a host of viruses.

The lab's interest in bats can be traced back to its 2013 paperpublished in "Science," which allowed Wang to secure a multi-million dollar grant through the Singapore National Research Foundation Competitive Research Programme to pursue his research. The paper connected a bat's ability to fly with its immune capabilities.

Bats are able to maintain high-powered flight, but this exerts metabolic and oxidative stress on their bodies that can be damaging to DNA. Despite this, bats display impressive longevity and low rates of cancer.

In ablog post, Bat Pack members noted thatthe evolutionary path of flight that favored mechanisms responsible forgene repair and tumor suppression may have also given bats the ability to carry deadly virusessuch as Ebola and Nipahwithout succumbing to symptoms.

Before tackling how exactly bats are immune to these diseases, the Bat Pack was tasked with creating a habitat that could support nectar-feeding bats, a type of bat that had never beforebeen artificially supported, Ng said. With the help of experts in zoology and bat-rearing, the group started a test colony of five bats to perfect their containment designs and diet formulas.

The colony has now expanded to 20 bats which have fullyacclimated to the habitat, and the group plans to expand their colony to60 bats by the middle of this year.

Since the bats were captured from the wild, the researchers facedpotentially confounding variables because they do not know the exact age or disease history of each bat. Still, Ng said the group is hopeful to piece together the various nuances of bat immune systems that can answer the question of how bats evade illness when infected with these deadly viruses.

Because bats are mammals and evidence exists that the genes contributing to their immunological abilities are similar to human genes, the researchers said they believe that their findings may translate to improvements in the field of human health and immunology.

Ng added that bats possess a unique combination of characteristics that are unlike typical model organisms such asrats or fruit flies.

"[Bats' characteristics]make them make them an ideal model for infectious disease, inflammation, cancer biology and anti-aging studies," he said.

The Chronicle is your source for Duke news, sports, culture and dialogue.

Subscribe to the Chronicle: Newsletter | The Dirt | Overtime

See more here:
'Bat Pack' at Duke-NUS allows researchers to study immunology - Duke Chronicle

Clinical and Vaccine Immunology

ASM Journal Press Releases

Clinical and Vaccine Immunology (CVI) enhances understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology.

Areas of focus include cellular and humoral immunity in humans and animals, immunological and immune-mediated disorders, immunotherapy, microbial immunology and microbial immune pathogenesis, veterinary and One Health immunology, development and standardization of immunological assays, and immunoepidemiology.

CVI is also committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.

View original post here:
Clinical and Vaccine Immunology

Immunology synergy drives Heat Bio’s acquisition play – WRAL Tech Wire

Posted Mar. 13, 2017 at 6:20 a.m.

Published: 2017-03-13 06:20:00 Updated: 2017-03-13 06:20:00

By ALLAN MAURER, NCBiotech Writer

Durham, N.C. Sometimes the Valley of Death can yawn wide and deep for pre-revenue life science companies, especially those trying to get a pharmaceutical to market.

And sometimes that requires some creative juggling to do expensive things with limited funds. Durham-based Heat Biologicsis a case in point.

When Heat licensed the immune system stimulating technology behind its ImPACT and ComPACT platforms from the University of Miami, it also licensed the tech behind Pelican Therapeutics Inc.

But we couldnt afford to develop both, so we spun off Pelican and funded that company independently, said Heat CEO Jeff Wolf in an exclusive interview with the North Carolina Biotechnology Center.

Early in March 2017, Heat acquired an 80 percent controlling interest in Pelican. The company said combining its technology with Pelicans and possibly other immunotherapies provides a synergistic treatment expected to be more effective than those used alone.

Pelicans T cell co-stimulator PTX-25 has the potential to boost the durability of T cell response when used with Heats other technologies, for instance.

Not only our technology, but any immunotherapy works best with other synergistic immunotherapies, Wolf said. Thats why we re-acquired Pelican. So its not going to be one treatment, but multiple ones. Were developing a portfolio of therapies that combine for a more lasting and sustained benefit against cancer.

Pelican funding from Texas cancer institute to help fund clinicals

Austin-based Pelicans funding includes a $15.2 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas(CPRIT). The highly competitive CPRIT awards include rigorous vetting of a winning firms technology.

That should enable the company to advance multiple products through preclinical development and at least one program through a 70-patient Phase 1 clinical trial, Heat said.

NCBiotech provided early support

After Heat was founded in 2008, the North Carolina Biotechnology Center helped recruit the company to the state and provided Heat its first outside funding, a $225,000 Strategic Growth Loan. That opened doors to more investment opportunity for Wolf. Heat was able to repay the loan well ahead of schedule as other investment support came in. NCBiotech also supported the company with its first offices in North Carolina, plus an internship and early business connectivity.

The connections between Heat, Pelican, and Shattuck Labs, a firm developing technology licensed from Heat, include the chair of Heats scientific and clinical advisory board, Taylor Schreiber, M.D., Ph.D. Schreiber, formerly Heats chief scientific officer, now holds that position at Shattuck. And he is also chair of Pelicans scientific advisory board.

Schreiber an originator of Heat technology with Miami's Eckhard Podack

Schreiber, co-inventor of significant elements of Heats ImPACT andComPACT immunotherapy platforms, worked with the original inventor of Heats technologies, Eckhard Podack, M.D., Ph.D, at the University of Miamis immunology department, a leader in the field. We hired him (Schreiber) directly from the university, said Wolf. He knows the technologies well.

Wolf said that while Heat (Nasdq:HTBX) saw disappointing results from its Phase 2 bladder vaccine trials in November 2016, which slammed its stock price and led to a 22 percent staff reduction, the company is continuing to monitor patients for two years. He added that the trial did show an increase in patient T cells and in their activity at the cancer site.

He also said Heats small-cell lung cancer trials are generating positive results so far. Were looking at making an announcement and more results later this year.

Wolf said Heat believes its ImPACT and ComPACT technologies are platforms that can be applied to many forms of cancer and possibly infectious diseases.

In late 2016 Heat formed the wholly owned subsidiary Zolovax in Durham to apply its technology against infectious diseases, including the Zika virus.

The Zika program emerged from the same laboratory that originally developed Heats current platform technologies, and will be developed at the University of Miami Miller School of Medicine.

(logy synrgy

WRAL TechWire any time: Twitter, Facebook

See the original post here:
Immunology synergy drives Heat Bio's acquisition play - WRAL Tech Wire

Immunology and Infectious Diseases Journal Club – Gazette

Immunology and Infectious Diseases Journal Club

Thursday, March 2, 12-1:30 p.m.

Computer Lab B, Health Sciences Centre

Development of rapid and high throughput human 293T cell and yeast-based systems for expression and purification of AID/APOBECs, presented by Faezeh Borzooee, M.Sc. candidate.

Presented by Division of BioMedical Sciences

See more here:
Immunology and Infectious Diseases Journal Club - Gazette

Cue Biopharma Strengthens Scientific and Clinical Advisory Board … – Yahoo Finance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Cue Biopharma, Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its scientific/clinical advisory board (SAB). The new members include Kenneth Pienta, M.D.; Jacques Banchereau, Ph.D.; and Karolina Palucka, M.D., Ph.D. These new members join Cues industry-leading SAB, which consists of three experts in immunology, immuno-oncology and protein design.

We are very pleased with the additional knowledge and expertise that these three leading researchers and clinicians bring to our SAB in the fields of immunology and immuno-oncology, as Cue continues to advance its programs towards the clinic, said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma.

These new scientific/clinical advisory board members bring invaluable experience that complements our existing members, and we have already begun integrating them into our advisory function, said Steven Almo, Ph.D., Chair of the Department of Biochemistry at Albert Einstein College of Medicine, scientific founder of Cue and Chairman of the Cue Scientific and Clinical Advisory Board.

Cues scientific and clinical advisory board now contains six leading oncology, immuno-oncology, immunology and protein design experts:

About Cue Biopharma

Immune Responses, On Cue. Cue Biopharma(Cue) is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. Cue biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, Cue is led by a strong, experienced management team and scientific/clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170222005333/en/

Continue reading here:
Cue Biopharma Strengthens Scientific and Clinical Advisory Board ... - Yahoo Finance

Frontier Pharma: Versatile Innovation in Immunology Large … – Satellite PR News (press release)

Albany, New York, February 25, 2017:Market Research Hub includes new market research report Frontier Pharma: Versatile Innovation in Immunology Large Therapy Area Pipeline with a High Degree of Repositioning Potential to its huge collection of research reports.Immunology is a large therapy area characterized by disorders of the immune system specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

Request Free Sample Report http://www.marketresearchhub.com/enquiry.php?type=S&repid=970728

This disease area has a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 529 immunology pipeline products that act on first-in-class molecular targets, representing approximately 40% of the total immunology pipeline for which the molecular target was disclosed.

Due to a degree of crossover between immunology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

Approximately one-fifth of first-in-class pipeline products are in development for two or more indications within the therapy area. This presents an opportunity for companies to develop innovative products across multiple immune disorders, and therefore reach a larger pool of patients than products developed for single indications.

Scope

Browse Full Report with TOC http://www.marketresearchhub.com/report/frontier-pharma-versatile-innovation-in-immunology-large-therapy-area-pipeline-with-a-high-degree-of-repositioning-potential-report.html

Reasons to buy

Related Reports:-

Global 3D Cell Culture Scaffold Market Research Report 2017-http://www.marketresearchhub.com/report/global-3d-cell-culture-scaffold-market-research-report-2017-report.html

Global Sugar Sphere Market Professional Survey Report 2017- http://www.marketresearchhub.com/report/global-sugar-sphere-market-professional-survey-report-2017-report.html

Global Human Milk Oligosaccharides Market 2016 Industry, Analysis, Research, Share, Growth, Sales, Trends, Supply, Forecast to 2021-http://www.marketresearchhub.com/report/global-human-milk-oligosaccharides-market-2016-industry-analysis-research-share-growth-sales-trends-supply-forecast-to-2021-report.html

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRHs expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

See the article here:
Frontier Pharma: Versatile Innovation in Immunology Large ... - Satellite PR News (press release)

Frontier Pharma: Versatile Innovation in Immunology Report 2017 – Large Therapy Area Pipeline with a High Degree of … – Yahoo Finance

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential" drug pipelines to their offering.

Immunology is a large therapy area characterized by disorders of the immune system - specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

This disease area has a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 529 immunology pipeline products that act on first-in-class molecular targets, representing approximately 40% of the total immunology pipeline for which the molecular target was disclosed.

Due to a degree of crossover between immunology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

Approximately one-fifth of first-in-class pipeline products are in development for two or more indications within the therapy area. This presents an opportunity for companies to develop innovative products across multiple immune disorders, and therefore reach a larger pool of patients than products developed for single indications.

Scope

- What are the key points of overlap in the pathophysiology of immune disorders?

- What is the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products?

- Which molecule types and molecular targets are most prominent within the pipeline?

- Which first-in-class targets are most promising?

- Do immunology products attract high deal values, and which specific product types are able to attract the highest values?

- Which molecule types and molecular targets dominate the deals landscape?

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 The Case for Innovation in the Immunology Market

4 Introduction

5 Pipeline Landscape Assessment

6 Immunology Signaling Network, Disease Causation and Innovation Alignment

7 First-in-Class Target and Pipeline Program Evaluation

8 Strategic Consolidations

9 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/z8fppq/frontier_pharma

View source version on businesswire.com: http://www.businesswire.com/news/home/20170221005737/en/

Go here to see the original:
Frontier Pharma: Versatile Innovation in Immunology Report 2017 - Large Therapy Area Pipeline with a High Degree of ... - Yahoo Finance

Majoring in defense: UAB’s new Undergraduate Immunology Program – The Mix

It doesnt matter whether you live in Beverly Hills or a Brazilian favela every human being is only a few inches away from disaster. From birth to death, on our arms, legs and everywhere else, each of us carries microbes that would love to get under our skin and reproduce, with potentially fatal results. A paper cut, an insect bite, an untimely rubbing of the eyes it takes very little for bacteria, viruses and other invaders to get inside and start wreaking havoc.

When that happens, the invaders are quickly surrounded by some of the billions of immune cells on constant patrol in our bodies. This finely coordinated attack is more complex than any human military organization. The immune system can be divided into two main categories innate and adaptive but there are LOTS of subdivisions: macrophages, natural killer cells, granulocytes, neutrophils, T and B cells, plasma cells, memory cells, regulatory T cells and so on. The list is long, and growing longer all the time with new discoveries. In recent years, researchers have learned how to target specific immune cells in new treatments for everything from cancer to rheumatoid arthritis. But there is much more to do.

Every year, hundreds of thousands of people die from infection by HIV, tuberculosis and the malaria-causing parasite Plasmodium. Although new checkpoint inhibitors have extended the lives of Jimmy Carter and many others, much more research is needed to help the 7+ million people worldwide who die each year from cancer. And heart disease, the leading cause of death on the planet, has a strong immune component as well.

Essentially all human diseases have an immune component, says Frances Lund, Ph.D., chair of the UAB School of Medicine Department of Microbiology. The future cures or treatments for many of the diseases that are of national and global concern will be dependent on our ability to successfully modulate the immune system.

With UABs new Undergraduate Immunology Program, which launches in fall 2017, students get a front-row seat to the life-and-death struggle going on inside us all and an ideal springboard for careers in medicine, academic research, industry and more. This is a cutting-edge major, says Louis Justement, Ph.D., director of the program, and a professor in the microbiology department. Students will get comprehensive experience in the scientific process, critical thinking, problem solving, scientific methodology and in communicating science. Our goal is to prepare students for the challenges and opportunities of the future and build up a pipeline of young immunologists to tackle the pressing problems of the 21st century.

Louis Justement, Ph.D. (School of Medicine) and Vithal Ghanta, Ph.D. (College of Arts and Sciences) are veteran researchers and educators of young scientists. "This is a cutting-edge major," Justement says. "Our goal is to prepare students for the challenges and opportunities of the future."

The Undergraduate Immunology Program is the only one of its kind in the Southeast, and one of a handful in the country, notes Vithal Ghanta, Ph.D., the programs co-director and a professor in the UAB College of Arts and SciencesDepartment of Biology. It is modeled on UABs Undergraduate Neuroscience Program, which has attracted elite students from across the country over the past eight years. Both programs are interdepartmental majors between the College of Arts and Sciences and School of Medicine.

This represents a true collaboration between the departments of Biology and Microbiology, says Lund. We believe that this unique educational opportunity will not only attract students who are passionate about science and medicine, but will perfectly prepare those students to take on the scientific and clinical challenges of the 21st century here in Alabama and across the world.

There are more than 100 faculty at UAB focusing on basic or clinical immunology, in 15 departments and four schools. Immunology and infectious diseases research at UAB is supported by $182 million in federal funding. Immunology has always been one of the strongest areas of research here, Justement says. Students will be able to choose among research opportunities in dozens of UAB labs, contributing to work that is targeting everything from cancer vaccines to next-generation asthma treatments. Students coming through our program have the ability to be integral members of labs across campus, Ghanta says. They can start as early as the freshman year, depending on their experience and ability to handle other coursework. By their junior year, all students in the major will be required to begin working in a UAB lab.

The interaction between the College of Arts and Sciences and School of Medicine faculty is critical, Justement says. Vithal and her colleagues know exactly how to work with undergraduates and help them learn. Meanwhile, Justement has years of experience preparing leaders in the lab as associate director of UABs Medical Scientist Training Program. People like me on the graduate side, since we are constantly working with graduate students and medical students, know what it takes to succeed in those arenas, and have insight on how curricula can prepare undergraduates to achieve, he says.

Our goal is to give undergraduate students a very solid foundation, adds Ghanta. They will be exposed to the various sub-fields of immunology in graduate school or medical school; we want to make sure they have a solid foundation to build on. Ghanta has taught a popular undergraduate immunology course in the Department of Biology for years. She says she regularly gets emails from former students who are now in medical school, letting me know that having this undergraduate immunology really helps them."

More than 100 faculty at UAB focus on basic or clinical immunology, in 15 departments and four schools, with $182 million in federal research support.

The first two years of the program are largely focused on overall university requirements and foundational science courses. But in order to let students jump right in, Justement and Ghanta have designed Current Topics in Immunology, a teaser course that shines new light on hot topics in the media. Justement says hell tell the story of a doctor who was cured of Ebola but then almost lost his vision later, because the virus was able to survive within his eyes. The reason is these are immune-privileged sites that need to be protected from the immune response, and it turns out the pathogen is able to take advantage of this, he says.

In their second year, students will take part in a seminar where investigators from across the university will share details on research in their labs. The students will get an idea of whose work sounds neat, who they would want to work with and why its important, Justement says.

In their junior and senior years, students in the program will take in-depth courses that delve into the fundamental cellular and molecular processes that control the immune response. This will provide them with a solid appreciation of how the immune system works as a whole, Ghanta says. Then, she adds, students will build on this knowledge by further exploring the interactions between the immune system and pathogens that try to subvert, or escape, the normal surveillance mechanisms used to detect and destroy them. Finally, students will learn about the dark side of the immune response, Justement says. When things go wrong it leads to numerous life-threatening diseases, including autoimmunity, asthma and chronic inflammation that in turn can cause heart disease, diabetes or cancer.

Essentially all human diseases have an immune component. The future cures or treatments for many of the diseases that are of national and global concern will be dependent on our ability to successfully modulate the immune system. Frances Lund, Ph.D., chair of the UAB Department of Microbiology.

Justement and Ghanta have formed a committee with the directors of the Undergraduate Neuroscience Program and leaders of the recently launched Undergraduate Program in Genetic and Genomic Sciences, and a new major in informatics that is now being developed. Soon, UAB will be able to offer students a suite of biomedical undergraduate programs, Justement says, all well suited to preparing them for professional and graduate school."

There are many opportunities to cross-fertilize among the specialties, Justement adds. There is neuro-immunology, tumor immunology and bioinformatics, just to name a few, he says. Students will be able to tailor their studies to the areas where they have the most interest. Well be able to make an amazing, unique educational experience even better.

The Undergraduate Immunology Program will help retain top students from the Birmingham area, and throughout Alabama, Justement says. But were also looking to expand our national footprint. UAB is creating a unique position in the world of undergraduate education."

Here is the original post:
Majoring in defense: UAB's new Undergraduate Immunology Program - The Mix

Remicade: Driving Down Merck’s Immunology Franchise – Market Realist

Merck and Companys Valuation after Its 4Q16 Earnings Release PART 6 OF 10

One of Merck and Co.s (MRK) blockbuster drugs, Remicade is one of the top-selling drugs for the treatment of inflammatory disorders. However, after the loss of exclusivity in the European markets in February 2015, Merck has reported a consistent decline in Remicade revenues. Apart from Merck, Johnson &Johnson (JNJ) also has marketing rights for Remicade in several countries outside Europe.

Remicades revenues fell~32% to $269 million in 4Q16, compared to $396 million in 4Q15. This was mainly due to the entry of generic competitors and biosimilars following the loss of exclusivity in European markets.

Merck expects Remicades revenues to keep declining as a growing number of new patients prefer biosimilars over Remicade.

Apart from Remicade, Simponi is a drug from the Inflammatory franchise. Simponis revenues remained flat at ~$186 million in 4Q16, compared to its 4Q15 revenues of $185 million.

Zetia and Vytorin are the blockbuster drugs from Mercks Cardiovascular franchise. Both drugs are used to lower LDL cholesterol levels in the blood.

The combined revenues for these drugs fell to $874 million in 4Q16. For the US markets, the sales for Zetia declined in 4Q16 while the sales for Vytorin grew. Worldwide sales were affected due to loss of exclusivity of Vytorin in the US, while Zetia sales were nearly constant for 4Q16 compared to 4Q15.

The competitors for Zetia include Niaspan from AbbVie (ABBV) and Lipitor from Pfizer (PFE). Investors can consider the VanEck Vectors Pharmaceutical ETF (PPH), which holds ~5.2% of its total assets in Merck.

View post:
Remicade: Driving Down Merck's Immunology Franchise - Market Realist